Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jazz Pharmaceuticals (NASDAQ: JAZZ), a global biopharma company, has announced it will release its 2025 second quarter financial results on Tuesday, August 5, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss the results and provide business updates.
Participants are encouraged to register at least 15 minutes before the webcast through the company's website or direct registration link. A replay will be available in the Investors section of Jazz Pharmaceuticals' website. The company specializes in developing medicines for sleep disorders, epilepsy, and cancer treatments, with operations spanning multiple countries.
Jazz Pharmaceuticals (NASDAQ: JAZZ), un'azienda biofarmaceutica globale, ha annunciato che pubblicherà i risultati finanziari del secondo trimestre 2025 martedì 5 agosto 2025, dopo la chiusura del mercato statunitense. La società terrà una webcast audio dal vivo alle 16:30 EDT / 21:30 IST per discutere i risultati e fornire aggiornamenti aziendali.
Si invita i partecipanti a registrarsi almeno 15 minuti prima della diretta tramite il sito web della società o il link diretto di registrazione. Una replica sarà disponibile nella sezione Investitori del sito di Jazz Pharmaceuticals. L'azienda è specializzata nello sviluppo di farmaci per disturbi del sonno, epilessia e trattamenti oncologici, con attività in diversi paesi.
Jazz Pharmaceuticals (NASDAQ: JAZZ), una compañía biofarmacéutica global, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2025 el martes 5 de agosto de 2025, después del cierre del mercado estadounidense. La empresa realizará una transmisión en vivo por audio a las 4:30 p.m. EDT / 9:30 p.m. IST para discutir los resultados y ofrecer actualizaciones comerciales.
Se recomienda a los participantes registrarse al menos 15 minutos antes de la transmisión a través del sitio web de la compañía o mediante un enlace directo de registro. Una repetición estará disponible en la sección de Inversores del sitio web de Jazz Pharmaceuticals. La empresa se especializa en el desarrollo de medicamentos para trastornos del sueño, epilepsia y tratamientos contra el cáncer, operando en varios países.
Jazz Pharmaceuticals (NASDAQ: JAZZ)는 글로벌 바이오제약 회사로서 2025년 2분기 재무 실적을 2025년 8월 5일 화요일 미국 시장 마감 후에 발표할 예정입니다. 회사는 오후 4시 30분 EDT / 오후 9시 30분 IST에 실적 발표 및 사업 업데이트를 위한 라이브 오디오 웹캐스트를 진행합니다.
참석자들은 웹캐스트 시작 최소 15분 전에 회사 웹사이트나 직접 등록 링크를 통해 등록할 것을 권장합니다. 재방송은 Jazz Pharmaceuticals 투자자 섹션에서 이용할 수 있습니다. 이 회사는 수면 장애, 간질, 암 치료제 개발을 전문으로 하며 여러 국가에서 사업을 운영하고 있습니다.
Jazz Pharmaceuticals (NASDAQ: JAZZ), une entreprise biopharmaceutique mondiale, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2025 le mardi 5 août 2025, après la clôture du marché américain. La société organisera une webdiffusion audio en direct à 16h30 EDT / 21h30 IST pour discuter des résultats et fournir des mises à jour sur ses activités.
Les participants sont invités à s'inscrire au moins 15 minutes avant la diffusion via le site web de l'entreprise ou un lien d'inscription direct. Une rediffusion sera disponible dans la section Investisseurs du site de Jazz Pharmaceuticals. L'entreprise est spécialisée dans le développement de médicaments pour les troubles du sommeil, l'épilepsie et les traitements contre le cancer, avec des opérations dans plusieurs pays.
Jazz Pharmaceuticals (NASDAQ: JAZZ), ein globales Biopharma-Unternehmen, hat angekündigt, seine Finanzergebnisse für das zweite Quartal 2025 am Dienstag, den 5. August 2025, nach Börsenschluss in den USA zu veröffentlichen. Das Unternehmen wird um 16:30 Uhr EDT / 21:30 Uhr IST ein Live-Audio-Webcast abhalten, um die Ergebnisse zu besprechen und Geschäftsaktualisierungen zu geben.
Teilnehmer werden gebeten, sich mindestens 15 Minuten vor dem Webcast über die Website des Unternehmens oder einen direkten Registrierungslink anzumelden. Eine Aufzeichnung wird im Investor-Bereich der Jazz Pharmaceuticals-Website verfügbar sein. Das Unternehmen ist auf die Entwicklung von Medikamenten für Schlafstörungen, Epilepsie und Krebsbehandlungen spezialisiert und ist in mehreren Ländern tätig.
- None.
- None.
Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
Jack Spinks
Senior Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-second-quarter-financial-results-on-august-5-2025-302500657.html
SOURCE Jazz Pharmaceuticals plc
FAQ
When will Jazz Pharmaceuticals (JAZZ) report Q2 2025 earnings?
What time is Jazz Pharmaceuticals' Q2 2025 earnings call?
How can investors access Jazz Pharmaceuticals' Q2 2025 earnings call?
What are Jazz Pharmaceuticals' main business areas?
Where can investors find the replay of Jazz Pharmaceuticals' Q2 2025 earnings call?
